U.S. markets open in 3 hours 40 minutes
  • S&P Futures

    4,170.25
    +12.50 (+0.30%)
     
  • Dow Futures

    34,322.00
    +66.00 (+0.19%)
     
  • Nasdaq Futures

    13,405.25
    +101.75 (+0.76%)
     
  • Russell 2000 Futures

    2,232.00
    +6.50 (+0.29%)
     
  • Crude Oil

    66.79
    +0.52 (+0.78%)
     
  • Gold

    1,868.40
    +0.80 (+0.04%)
     
  • Silver

    28.68
    +0.42 (+1.49%)
     
  • EUR/USD

    1.2226
    +0.0070 (+0.57%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.40
    +0.59 (+3.14%)
     
  • GBP/USD

    1.4201
    +0.0063 (+0.45%)
     
  • USD/JPY

    108.9320
    -0.2680 (-0.25%)
     
  • BTC-USD

    45,071.75
    -64.24 (-0.14%)
     
  • CMC Crypto 200

    1,252.03
    +54.12 (+4.52%)
     
  • FTSE 100

    7,057.06
    +24.21 (+0.34%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

Recap: Anika Therapeutics Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Anika Therapeutics (NASDAQ:ANIK) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 72.09% year over year to $0.12, which beat the estimate of ($0.01).

Revenue of $32,688,000 rose by 9.79% year over year, which missed the estimate of $33,500,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Anika Therapeutics hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Mar 04, 2021

View more earnings on ANIK

Time: 05:00 PM

ET Webcast URL: http://public.viavid.com/player/index.php?id=143334

Technicals

Company's 52-week high was at $47.48

Company's 52-week low was at $22.01

Price action over last quarter: Up 12.48%

Company Profile

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.